In this interview, a PI describes their use of sequencing technologies for research on inheritedeye diseases. They regularly engage in large scale collaborative studies and have sequenced over 3,000 patients with eye diseases. Their lab utilizes various Oxford Nanopore sequencers internally. Additionally, they utilize their core and service providers for Illumina sequencing, but as a smaller lab, they do not purchase Illumina sequencers themselves. They are familiar with Illumina, Oxford Nanopore, Thermo Fisher, PacBio, Ultima, and MGI / Complete Genomics. Their main sequencing focus is generating ultra-long reads, for which they view Oxford Nanopore’s technology as ideal, especially considering the zero CapEx model offered. Their major pain points are the price and logistics of utilizing sequencing services, the availability of bioinformaticians, and the difficulty of keeping up with regularly changing chemistry for in-house sequencers. They think winning in the NGS space will require engaging beta testers to drive new science forward to demonstrate the value of one platform versus another.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.